论文部分内容阅读
早在1964年就已认识到,莆萄糖-6-磷酸脱氢酶(G-6-PD)的多形性可用于分析人类恶性疾病的克隆起源。在造血分析中,随着体外克隆技术的发展,结合选择性细胞标志物G-6-PD的酶型分析,能提供克隆形成细胞的正常或癌性起源的直接证据,确定发生“突变”的细胞水平。近年来,在“克隆性血液病”的研究中已有许多报道。本文就体外克隆技术联合G-6-PD标记克隆起源的有关方面,作一简要综合。细胞体外培养无标志作用祖细胞体外培养技术,可以对正常人和骨髓功能异常的病人作造血调节分析,它能提供可以识别的骨髓成分的数目、增殖潜能、分化
As early as 1964, it has been recognized that the polymorphism of glucose-6-phosphate dehydrogenase (G-6-PD) can be used to analyze the clonal origin of human malignancies. In hematopoietic analysis, with the development of in vitro cloning techniques, coupled with the enzymatic analysis of the selective cell marker G-6-PD, direct evidence of the normal or cancerous origin of the clonogenic cells can be provided confirming that a “mutation” Cell level. In recent years, there have been many reports in the study of “clonogenic hematological diseases”. In this paper, in vitro cloning technology combined with the origin of G-6-PD marker clones, make a brief synthesis. In vitro culture of cells without markers The progenitor cells in vitro culture technique allows for the analysis of hematopoietic regulation in patients with abnormalities of normal human and bone marrow, providing identifiable numbers of marrow components, proliferative potential, differentiation